股票

Galloping ahead – what our China Equity team expects from the Year of the Horse (只提供英文版本)

As China welcomes the Year of the Horse on 17 February 2026, anticipation is building. The Horse, symbolizing strength, freedom, and speed, points to a year likely marked by vitality and dynamic change. Traditionally, the Year of the Horse is associated with progress and noteworthy achievements. It embodies traits such as optimism and resilience, suggesting individuals and businesses alike may take a bold and energetic approach to new opportunities as they arise.

In this spirit, our China Equity Portfolio Management Team is pleased to share their expectations for the year ahead, what they are most looking forward to, and how they plan to navigate the opportunities and challenges of the Year of the Horse.

Shao Ping Guan
SHAO PING GUAN

Head of China Equity

I’m looking forward to a year packed with meaningful progress across policy, technology, and culture. Fiscal reforms could help shift local government focus from manufacturing toward services and consumption, while the expansion of the defined contribution pensions system strengthens both retirement security and capital markets. We may also see significant progress in strategic technologies – from DUV (deep ultra-violet) lithography, used in semiconductor manufacturing, to foundation AI models and World Model based autonomy in driving and robotics. Add in the potential for successful reusable rocket launches and the rise of grassroots sports leagues like the Jiangsu Football City League and the Guizhou Village League, and the year ahead promises plenty of positive momentum.

Kevin You
KEVIN YOU

Portfolio Manager

I’m looking forward to seeing China develop large-scale, fully automated AI factories. These “lights out” facilities would use advanced AI agents to manage production, coordinate robots, handle supplies, maintain equipment, and ensure quality. Linking these systems across industries would turn today’s factories into highly autonomous smart facilities. With China’s strong manufacturing base, robotics capacity, fast networks, and domestic AI models, this level of automation looks achievable – cutting costs, and strengthening control over core industrial technology.

CHRISTINA CHUNG
CHRISTINA CHUNG

Portfolio Manager

I recently toured a fast growing data center component maker’s factory, and the scale-up has been remarkable. The site now runs with more than 1,000 robotic arms, an evolution from their early adoption of robotics more than 15 years ago. In that time, the workforce has dropped 40% while revenue has climbed by a similar margin. They’ve recently opened a new Thailand facility for next gen products, though ramping up has been challenging due to a shortage of skilled engineers in control systems and process optimization. With more Chinese manufacturers expanding overseas, I plan to visit these new production hubs in the coming year which should reveal fascinating insights into how China’s industrial footprint is globalizing.

STEPHEN CHOW
STEPHEN CHOW

Portfolio Manager and Research Analyst

I’m excited for the upcoming launch of the highly anticipated foldable phone from the Cupertino based global smartphone leader, which is currently being produced in China. It’s expected to generate huge demand, marking one of the company’s most significant design advances in years, with a rumoured crease free display that showcases its trademark craftsmanship. The larger screen, combined with the brand’s intuitive operating system, could meaningfully boost productivity and create a standout user experience.

CATHERINE CHAN
CATHERINE CHAN

Research Analyst

A key trend in the coming year is likely to be the further rise in demand for commodities driven by new technology trends – AI, electric vehicles, charging networks, humanoid robots, and next generation batteries such as solid state technology. While many may see commodities as relatively dull and low growth, the build out of AI infrastructure, energy storage, and ultra high voltage transmission is sharply increasing the need for copper, aluminum, tungsten, and glass fibre. With global supply still tight, I’m looking forward to seeing metal prices push to new highs this year.

THOMAS ZHU
THOMAS ZHU

Research Analyst

One thing I look forward to is the upcoming launch of the third generation Optimus, Tesla’s humanoid robot. This new version is expected to deliver human level hand dexterity and learn autonomously by watching human demonstrations – bringing it much closer to becoming a truly capable, general purpose assistant for dangerous, repetitive, or mundane tasks. It also opens the door for Chinese industrial suppliers to benefit, leveraging their strength in high quality, low cost mass production as global demand for advanced robotics accelerates.

MANDY SHEK
MANDY SHEK

Research Analyst

Artificial Intelligence in China continues to gallop (pun intended), and we’ll likely see a wave of fresh large language model (LLM) updates around Chinese New Year and in the months ahead. The annual Spring Festival Gala should also bring more entertaining humanoid robot performances and interactive moments for viewers. As local LLM players close the gap with global peers, 2026 should deliver more consumer facing applications – making photo and video editing, food ordering, trip planning, and even e commerce purchases just a few clicks away. I’m excited to see how AI will keep shaping our daily lives.

ZICHEN XU
ZICHEN XU

Research Analyst

I see the coming year as one marked by rising optimism. After several years of cautious sentiment, Chinese households are turning more positive – moving savings into brokerage accounts and buying market linked insurance products. With property no longer the sole pillar of wealth, a younger generation may finally break free from the shackle of 30-year mortgages and build larger portions of their savings through the equity market. If this shift takes hold, it could mark a fresh beginning for China’s households and financial markets.

ALEC SO
ALEC SO

Research Analyst

One thing I look forward to is the rapid progress in autonomous mobility and humanoid robotics. Robotaxi pilots are scaling quickly across China, pushing the technology closer to meaningful commercial use. At the same time, optimism around humanoid robots is set to build as the industry approaches key mass production milestones later this year. Together, these developments could unlock new applications and spark another wave of innovation across China’s smart manufacturing and AI ecosystem.

TERRANCE LIU
TERRANCE LIU

Research Analyst

Following an intense food delivery price war in 2025, I expect to see a clear rebound in offline consumer traffic across China in 2026. Policy support should also strengthen, with the government likely to roll out more favourable measures, such as targeted subsidies, for service sector businesses. This combination sets the stage for a broader consumption recovery, especially in the catering industry, which I believe the market has underestimated.

SHIRLEY NG
SHIRLEY NG

Research Analyst

I look forward to seeing Chinese consumer brands continue to redefine themselves on the global stage. At the recent Consumer Electronics Show (CES), one of the world’s most well known exhibitions for technology and innovation, we saw a wave of smart home and AI products from China – from household cleaners that are no longer constrained by stairs to AI robot pets designed to provide companionship and emotional value. Meanwhile, Chinese electric vehicles and even lifestyle products like pop toys are becoming increasingly visible around the world. This evolution shows how perceptions are shifting – from low cost, low quality to more affordable products with strong design and technology. It will be exciting to watch Chinese brands gain recognition not just for price, but for quality and creativity.

ALEX JIANG
ALEX JIANG

Research Analyst

One thing I’m looking forward to is the continued rise of China’s biotech sector, which has made impressive strides in drug innovation. Licensing out partnerships with well-known global pharmaceutical companies are expanding rapidly, and many of these pipeline drugs should deliver strong clinical data in the coming year, with some even approaching potential FDA approval. This growing global recognition – paired with accelerating R&D capabilities – sets the stage for another exciting year for China’s biotech ecosystem.

The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. We assume no obligation to update any forward-looking statement.

Securities mentioned in this document are for illustrative purposes only and do not constitute a recommendation or solicitation to buy or sell any particular security. These securities will not necessarily be comprised in the portfolio by the time this document is disclosed or at any other subsequent date.

Investing involves risk. The value of an investment and the income from it may fall as well as rise and investors might not get back the full amount invested.

Past performance does not predict future returns. If the currency in which the past performance is displayed differs from the currency of the country in which the investor resides, then the investor should be aware that due to the exchange rate fluctuations the performance shown may be higher or lower if converted into the investor’s local currency.

This is for information only and not to be construed as a solicitation or an invitation to make an offer to buy or sell any securities. The views and opinions expressed herein, which are subject to change without notice, are those of the issuer or its affiliated companies at the time of publication. The data used is derived from various sources and assumed to be accurate and reliable at the time of publication. but it has not been independently verified; its accuracy or completeness is not guaranteed and no liability is assumed for any direct or consequential losses arising from its use, unless caused by gross negligence or willful misconduct. The duplication, publication, extraction or transmission of the contents, irrespective of the form, is not permitted, except for the case of explicit permission by Allianz Global Investors.

This material has not been reviewed by any regulatory authorities.


This document is being distributed by the following Allianz Global Investors companies: In Australia, this material is presented by Allianz Global Investors Asia Pacific Limited (“AllianzGI AP”) and is intended for the use of investment consultants and other institutional/professional investors only, and is not directed to the public or individual retail investors. AllianzGI AP is not licensed to provide financial services to retail clients in Australia. AllianzGI AP is exempt from the requirement to hold an Australian Foreign Financial Service License under the Corporations Act 2001 (Cth) pursuant to ASIC Class Order (CO 03/1103) with respect to the provision of financial services to wholesale clients only. AllianzGI AP is licensed and regulated by Hong Kong Securities and Futures Commission under Hong Kong laws, which differ from Australian laws; in the European Union and South Africa, by Allianz Global Investors GmbH, an investment company in Germany, authorized by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin) and authorized and regulated in South Africa by the Financial Sector Conduct Authority; in the UK, by Allianz Global Investors (UK) Ltd. company number 11516839, authorised and regulated by the Financial Conduct Authority (FCA); in Switzerland, by Allianz Global Investors (Schweiz) AG, authorised by the Swiss financial markets regulator (FINMA); in HK, by Allianz Global Investors Asia Pacific Ltd., licensed by the Hong Kong Securities and Futures Commission; in Singapore, by Allianz Global Investors Singapore Ltd., regulated by the Monetary Authority of Singapore [Company Registration No. 199907169Z]; in Japan, by Allianz Global Investors Japan Co., Ltd., registered in Japan as a Financial Instruments Business Operator [Registered No. The Director of Kanto Local Finance Bureau (Financial Instruments Business Operator), No. 424], Member of Japan Investment Advisers Association, the Investment Trust Association, Japan and Type II Financial Instruments Firms Association; In mainland China, it is for Qualified Domestic Institutional Investors scheme pursuant to applicable rules and regulations and is for information purpose only. in Taiwan, by Allianz Global Investors Taiwan Ltd., licensed by Financial Supervisory Commission in Taiwan; and in Indonesia, by PT. Allianz Global Investors Asset Management Indonesia licensed by Indonesia Financial Services Authority (OJK).

5171839

安聯投資

你正在離開此網站及轉至以下網站。此並不意味安聯環球投資亞太有限公司對經重新導向後之網站中所包含的信息給予任何批准或認可,而安聯環球投資亞太有限公司亦不會對有關此連結及其包含的資料承擔任何責任或義務。請注意經重新導向後之網站中可能包含未經認可向香港公眾人士提供的基金和投資策略。此外,亦請細閱經重新導向後之網站中的條款及細則、隱私及安全政策、或其他法律條款信息。如你按「繼續」,即表示您確認上述詳細信息並繼續訪問經重新導向後之網站。 如你有任何疑慮,請按「留在此頁」。

Welcome to Allianz Global Investors

選擇您的語言
  • English
  • 中文(繁體)
選擇您的身份
  • 個人投資者
  • 中介人
  • 其他投資者
  • 退休投資者
  • 安聯環球投資基金 
    • 安聯環球投資基金作為UCITS規例下的傘子型基金,旗下設有投資於固定收益證券、股票及金融衍生工具的多個不同附屬基金,每一附屬基金各具不同的投資目標及/或風險取向。

    • 所有附屬基金可投資於金融衍生工具,會涉及較高的槓桿、交易對手、流通性、估值、波幅、市場及場外交易風險。附屬基金的衍生工具風險承擔淨額最多為其資產淨值的50%。

    • 部份附屬基金的部份投資亦可投資於任何一項工具或工具的組合,例如固定收益證券、新興市場證券及/或按揭證券、資產擔保證券、房地產相關資產(尤其是房地產投資信託基金)及/或結構產品及/或衍生工具,該工具可能會涉及不同潛在風險(包括槓桿、交易對手、流通性、估值、波幅、市場、相關房地產價值及租金收入波動及場外交易風險)。

    • 部份附屬基金可投資於單一國家或行業〔尤其是小型股/中型股公司〕。相對於比較多元化的附屬基金,該等附屬基金或會因其集中投資而承擔較高風險。部份附屬基金須承受重大風險包括投資/一般市場、國家及區域、新興市場〔如中國內地〕、信貸能力/信貸評級/評級下調、違約、資產配置、利率、波幅及流通性、交易對手、主權債務、估值、信貸評級機構、公司特定、貨幣〔尤其是人民幣〕、人民幣債務證券及中國內地的稅務的風險。

    • 部份附屬基金可投資於可換股債券、高收益、非投資級別投資及未獲評級證券,須承擔較高風險(包括波動性、本金及利息虧損、信貸能力和評級下調、違約、利率、一般市場及流通性的風險),因此可對部份附屬基金的資產淨值構成不利影響 。可換股債券將受提前還款風險及股票走勢所影響,而且波幅高於傳統債券投資。

    • 部份附屬基金可將相當比例的資產投資於由非投資級別主權發行機構〔例如菲律賓〕所發行或擔保的附息證券,因而須承擔較高的流通性、信用/違約及集中程度的風險,以及較大波動及較高風險水平。因此投資者可會蒙受嚴重虧損。

    • 部份附屬基金可投資於歐洲國家。歐洲經濟及財政困境有可能會惡化,因而對此附屬基金構成不利影響(如增加歐洲投資所附帶的波動、流通性及貨幣的風險)。

    • 部份附屬基金或會透過滬/深港通或中國銀行間債券市場或其他海外投資渠道制度及╱或相關容許的其他方式而直接及╱或透過一切合資格工具而間接投資中國A股、中國B股及╱或中國債務證券市場故此須承受相關風險〔包括額度限制、規則及規例的更改、附屬基金匯回款項限制、交易限制、中國市場波動及不穩定、潛在的結算及交收困難、交易對手違約、中國經濟、社會和政治政策的變動及中國內地稅務等風險〕。

    • 部分附屬基金可採取以下策略,社會責任投資(「SRI」)(專屬評分)策略、SDG策略、可持續發展關鍵績效指標策略(相對)、綠色債券策略、多元資產可持續發展策略、可持續發展關鍵績效指標策略(絕對界線)、環境、社會及管治(「ESG」)評分策略及可持續發展關鍵績效指標策略(絕對)。如採取以上策略,附屬基金須承受策略相對的可持續投資風險〔如導致附屬基金在有利條件下放棄買入若干證券的機會,及╱或在不利條件下出售證券或倚賴來自第三方ESG研究數據供應商及內部分析的資料及數據,其可能帶有主觀成份、不完整、不準確或無法取得,及╱或與基礎廣泛的基金相比會減低風險分散程度〕。此外,部分附屬基金可能特別專注於被投資公司的溫室氣體排放效率,而非其財務表現。因此可能對相關附屬基金的表現構成不利影響。

    • 部份附屬基金可投資於固定分派百分比股份類別(AMf類股份)。投資者請注意,固定分派百分比不獲保證。該股份類別不能替代支付固定利息的投資。AMf類股份的分派百分比與該等股份類別或附屬基金的預期或過去收入或回報無關。如果附屬基金錄得負回報,固定分派百分比股份類別將繼續作出分派,因而可能對附屬基金的資產淨值構成不利影響。正數派息率並不代表正數回報。

    • 投資所涉及的風險可能導致投資者損失部份或全部投資金額。

    • 投資者不應單靠本〔網站/文件〕的資料而作出投資決定。

       

    :附屬基金派息由基金經理酌情決定。派息或從附屬基金資本中支付,或實際上從資本中撥付股息。這即等同從閣下原本投資金額及╱或從金額賺取的資本收益退回或提取部份款項。這或令每股資產淨值即時下降,及令可作未來投資的附屬基金資本和資本增長減少。因對沖股份類別參考貨幣與附屬基金結算貨幣之間的息差,有關對沖股份類別之分派金額及資產淨值會因而更受到不利影響,特別是若該等對沖股份類別正採用利率差距中性政策。股息派發適用於A/AM/AMg/AMi/AMgi/AQ類收息股份(每年/月/季派息)及僅作參考,並沒有保證。正數派息率並不代表正數回報。有關附屬基金股息政策詳情,請參閱銷售文件


    安聯環球投資亞洲基金

    • 安聯環球投資亞洲基金(「本信託」)乃遵照香港法例並根據信託契約而構成的傘子單位信託。安聯精選主題收益基金、安聯寰通收益及增長基金及安聯收益基金是本信託的附屬基金(每一「附屬基金」),投資於固定收益證券、股票及衍生工具,每一附屬基金各具不同的投資目標及/或風險取向。

    • 部份附屬基金須承受重大風險包括投資/一般市場、個別公司有關、新興市場、信貸能力╱信用評級╱調低信用評級、違約、波動性及流通性、估值、主權債務、主題集中程度、以主題為基礎的投資策略、交易對手、利率變動、國家及地區、及資產配置及貨幣〔如外匯管制,尤其是人民幣〕的風險,及因貨幣貶值對人民幣計價股份類別構成的不利影響。

    • 附屬基金可投資於可能高度缺乏流通性且容易出現價格大幅波動的資產抵押證券及按揭證券。此等工具可能較其他債務證券承受更大的一般市場風險、集中程度風險、信用和交易對手違約風險、流通性風險及利率風險。

    • 部份附屬基金可投資於高收益(非投資級別與未評級)投資及/或可換股債券,須承擔較高風險,如波動性、違約、利率變動、一般市場及流通性的風險,因此可對附屬基金的資產淨值構成不利影響 。

    • 所有附屬基金可投資於金融衍生工具,附屬基金會涉及較高的槓桿、交易對手、流通性、估值、波動性、市場及場外交易風險。運用衍生工具可能導致附屬基金承受超出原有投資款額的虧損。附屬基金的衍生工具風險承擔淨額最多為其資產淨值的50%。

    • 這項投資所涉及的風險可能導致投資者損失部分或全部投資金額。

    • 投資者不應僅就本網站而作出投資決定。

       

    註:附屬基金派息由基金經理酌情決定。派息或從基金收入及/或從資本中支付,這即等同從閣下原本投資金額及╱或從金額賺取的資本收益退回或提取部份款項。這或令每個收息單位資產淨值即時下降,及令可作未來投資的基金資本和資本增長減少。因對沖股份類別參考貨幣與附屬基金結算貨幣之間的息差,有關對沖股份類別之分派金額及資產淨值會因而更受到不利影響,特別是若該等對沖股份類別正採用利率差距中性政策。股息派發適用於A/AM/AMg/AMi/AMgi類收息股份(每年/月派息)及僅作參考,並沒有保證。正數派息率並不代表正數回報。有關附屬基金股息政策詳情,請參閱銷售文件。

請示意您已閱畢及明白有關重要資料。